CliffBio
small molecule

MIVACRON

MIVACURIUM CHLORIDE

Loss of exclusivity—loss of exclusivity
CompanyAbbVie Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameMIVACRON
Active ingredientMIVACURIUM CHLORIDE
StrengthEQ 20MG BASE/10ML (EQ 2MG BASE/ML)
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalJanuary 1992
Marketing statusDISCN

More from AbbVie Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

MIVACRON patent cliff — loss of exclusivity — | CliffBio